uniQure (QURE)
(Delayed Data from NSDQ)
$4.91 USD
+0.03 (0.61%)
Updated May 14, 2024 04:00 PM ET
After-Market: $4.91 0.00 (0.00%) 6:48 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
uniQure N.V. [QURE]
Reports for Purchase
Showing records 81 - 100 ( 153 total )
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Time Is of the Essence in Huntington''s Disease; AMT-130 IND On Track for 2H18
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Compelling Peer HD Data; But Deep Brain Penetration Likely to Remain an Issue; Enter AMT-130
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Vagaries of the Market Creates an Opportunity; Reiterate Buy and $35 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Bio-bucks Galore, AAV Vectors and CNS Targets Likely to Remain in Focus. Increasing Target to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Seeking Alpha in a High Beta Environment
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
What''s Good for Spark Could Be Better for uniQure
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
SPARK-ing a Coup and Jumping the Queue; Initiating at Buy and $28 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
We are terminating coverage due to the departure from the firm of the covering analyst
Provider: H.C. Wainwright & Co., Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
2016 World Orphan Drug Congress Recap: Emerging Trends in Rare Disease Therapeutics
Provider: Rodman & Renshaw, Co.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Restructuring Stretches Cash Runway to 2019; Adjusting PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
A Multifaceted Gene Therapy Company; Assuming Coverage With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Gene Therapy Platform Makes Clinical Headway in Hemophilia B and Orphan Diseases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Modularity of Gene Therapy Platform Underscored in Huntington''s Disease Proof-of-Concept Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Making Gene Therapy a Commercial Reality with a De-risked Technology Platform; Assuming Coverage with a Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Spotlight on Cell and Gene Therapy at ASH 2015
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.